ArticleOncotarget2019
Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery.
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Beyond autologousMolecular therapy. Oncology · 2026Review
- Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside.Drug delivery · 2025Review
- Potential of Platelet-Based Drug Delivery System for Treating Peritoneal Metastasis of Gastric Cancer.Cancer science · 2025Article
- Tailoring cell-inspired biomaterials to fuel cancer therapy.Materials today. Bio · 2025Review
- Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.Current opinion in hematology · 2025Review
- Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review.Frontiers in bioengineering and biotechnology · 2025Review
- The role of protease-activated receptors (PARs) in the functioning of platelets and platelet-derived microparticles (PMPs).Frontiers in molecular biosciences · 2025Review
- Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.Biomarker research · 2024Review
- Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells.Molecular diversity · 2024Article
- Platelet-derived microparticles and their cargos: The past, present and future.Asian journal of pharmaceutical sciences · 2024Review
- Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.Journal of biomedical science · 2023Review
- Platelets for cancer treatment and drug delivery.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.Biomolecules · 2022Review
- Natural cell based biomimetic cellular transformers for targeted therapy of digestive system cancer.Theranostics · 2022Review
- Fibrinogen Mitigates Prion-Mediated Platelet Activation and Neuronal Cell Toxicity.Frontiers in cell and developmental biology · 2022Article
- Microvesicles: the functional mediators in sorafenib resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Research landscape of exosomes in platelets from 2000 to 2022: A bibliometric analysis.Frontiers in cardiovascular medicine · 2022Article
- Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects.Frontiers in pharmacology · 2022Review
- Platelet-rich plasma-derived extracellular vesicles: A superior alternative in regenerative medicine?Cell proliferation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug targeting has opened a new paradigm in therapeutics with development of delivery vectors like liposomes and polymeric nanoparticles. Although their clinical application is crippled by limited biological adaptability. Off-target toxicity and biocompatibility still remains one of the critical problems in anticancer therapeutics that can be life-threatening. Here we report a quick, simple and facile method of engineering human platelets to generate drug loaded platelet-derived microparticles (PMPs) by top-down approach, which are biocompatible and naturally target leukemia cells. Drug loaded PMPs and cancer cell uptake were characterized by flow cytometry, confocal microscopy, Nanoparticle Tracking Analysis and fluorimetry. Effective drug delivery was tested in cancer cell lines as well as in clinical samples from leukemia patients. We explored that PMPs are capable of carrying multiple drug payloads, have long shelf life and can be harvested in large quantity in short period. Importantly, PMPs exhibited remarkably higher toxicity towards cancer cells than free drug and had lower escape into extravascular spaces. Transfer of drug to cancer cells of leukemia patients was significantly higher than free drug, when delivered through PMPs. Our experiments validated therapeutic application of PMPs as biocompatible drug delivery vector against cancer cells with minimal off-target delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.